SCHEMBL30165007

SCHEMBL30165007

c1cn(CC2CNC2)nn1

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.36
MAOA P21397 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17108208 0.85 HRH4 (0.35) CYP19A1MAOA
Hydrochloric Acid SCHEMBL17048491 0.84 HRH4 (0.34) CYP19A1MAOA
SCHEMBL9965874 0.81 CYP19A1 (0.34) CYP19A1
SCHEMBL9965871 0.81 CYP19A1 (0.34) CYP19A1
SCHEMBL4309077 0.81 MAOA (0.36) CYP19A1MAOA
SCHEMBL27989235 0.78 CYP2B6 (0.40) CYP19A1
SCHEMBL2877085 0.78 CYP2B6 (0.44) CYP19A1
SCHEMBL18325457 0.76 CYP2B6 (0.47) CYP19A1
SCHEMBL18325220 0.76 CYP2B6 (0.47) CYP19A1
SCHEMBL2573428 0.72 FDPS (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117858872-A Heterocyclic EGFR inhibitors for the treatment of cancer 缆图药品公司 2024-04-09 CN disclosed
WO-2022271612-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 WO disclosed